A Study to Test How SB756050 Affects Subjects With Type 2 Diabetes Mellitus After 6 Days of Dosing.

Phase 1 Completed 48 enrolled GlaxoSmithKline

RandomizedParallel-groupSingle-blindTreatment

Summary

This is an escalating dose study in subjects with T2DM, which will consist of four overlapping cohorts receiving 6 days of SB756050 to assess safety, pharmacokinetics, and pharmacodynamics.

Timeline

Start: 2008-08-11
Primary completion: 2009-03-03
Completion: 2009-03-03

Publications

Hodge RJ, Lin J, Vasist Johnson LS, Gould EP, Bowers GD, Nunez DJ; SB-756050 Project Team. Safety, Pharmacokinetics, and Pharmacodynamic Effects of a Selective TGR5 Agonist, SB-756050, in Type 2 Diabetes. Clin Pharmacol Drug Dev. 2013 Jul;2(3):213-22. doi: 10.1002/cpdd.34. Epub 2013 May 14.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SB-756050	Small molecule	15 mg	Oral
Subject	SB-756050	Small molecule	50 mg	Oral
Subject	SB-756050	Small molecule	150 mg	Oral
Subject	SB-756050	Small molecule	600 mg	Oral

A Study to Test How SB756050 Affects Subjects With Type 2 Diabetes Mellitus After 6 Days of Dosing.

Summary

Timeline

Publications

Drugs

Indications